Onkure Therapeutics 近日公布一项获得超额认购的1.5亿美元私募融资计划,所筹资金将主要用于加速其新一代Pi3kα泛突变选择性抑制剂在乳腺癌和血管异常适应症中的临床开发进程。该融资得到多家知名投资机构支持,反映出市场对其创新疗法前景的强烈信心。
公司表示,这笔资金将有力推动其核心候选药物走向临床后期研究,为相关疾病患者提供新的治疗希望。
Onkure Therapeutics 近日公布一项获得超额认购的1.5亿美元私募融资计划,所筹资金将主要用于加速其新一代Pi3kα泛突变选择性抑制剂在乳腺癌和血管异常适应症中的临床开发进程。该融资得到多家知名投资机构支持,反映出市场对其创新疗法前景的强烈信心。
公司表示,这笔资金将有力推动其核心候选药物走向临床后期研究,为相关疾病患者提供新的治疗希望。
Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.